Table 2.
Association between baseline HOMA-IR and long-term cardio-renal outcomes
| Outcome | n/N events (%) | Model 1 | p value | Model 2 | p value | Model 3 | p value |
|---|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | |||||
| Cardiorenal outcomes | |||||||
| Tertile 1 | 27/339 (8.0%) | (reference) | (reference) | (reference) | |||
| Tertile 2 | 37/332 (11.1%) | 1.31 (0.79–2.17) | 0.289 | 1.41 (0.84–2.39) | 0.197 | 1.74 (1.01–3.01) | 0.046 |
| Tertile 3 | 39/328 (11.9%) | 1.44 (0.88–2.35) | 0.149 | 1.64 (0.96–2.81) | 0.072 | 2.29 (1.28–4.09) | 0.005 |
| p value for trend across tertiles | NA | 1.19 (0.94–1.51) | 0.154 | 1.27 (0.98–1.65) | 0.076 | 1.49 (1.12–1.97) | 0.006 |
| per log unit increase | NA | 1.13 (0.95–1.35) | 0.163 | 1.19 (0.99–1.43) | 0.069 | 1.32 (1.09–1.60) | 0.004 |
| Renal composite or all-cause mortality | |||||||
| Tertile 1 | 23/343 (6.7%) | (reference) | (reference) | (reference) | |||
| Tertile 2 | 29/340 (8.5%) | 1.20 (0.69–2.10) | 0.511 | 1.25 (0.70–2.24) | 0.453 | 1.40 (0.76–2.56) | 0.278 |
| Tertile 3 | 34/333 (10.2%) | 1.48 (0.87–2.51) | 0.149 | 1.61 (0.89–2.90) | 0.116 | 2.06 (1.09–3.88) | 0.026 |
| p value for trend across tertiles | NA | 1.22 (0.93–1.58) | 0.145 | 1.27 (0.95–1.70) | 0.110 | 1.44 (1.05–1.97) | 0.023 |
| per log unit increase | NA | 1.12 (0.93–1.36) | 0.240 | 1.16 (0.95–1.43) | 0.151 | 1.25 (1.01–1.55) | 0.037 |
| Renal composite | |||||||
| Tertile 1 | 16/350 (4.6%) | (reference) | (reference) | (reference) | |||
| Tertile 2 | 23/346 (6.6%) | 1.38 (0.72–2.64) | 0.331 | 1.46 (0.72–2.93) | 0.293 | 1.87 (0.90–3.88) | 0.093 |
| Tertile 3 | 23/344 (6.7%) | 1.48 (0.78–2.81) | 0.235 | 1.51 (0.71–3.18) | 0.281 | 2.49 (1.11–5.60) | 0.028 |
| p value for trend across tertiles | NA | 1.20 (0.88–1.64) | 0.244 | 1.21 (0.84–1.74) | 0.305 | 1.55 (1.05–2.30) | 0.029 |
| per log unit increase | NA | 1.09 (0.87–1.37) | 0.443 | 1.11 (0.87–1.43) | 0.406 | 1.30 (1.00-1.68) | 0.048 |
| CV composite | |||||||
| Tertile 1 | 12/354 (3.4%) | (reference) | (reference) | (reference) | |||
| Tertile 2 | 15/354 (4.2%) | 1.22 (0.57–2.62) | 0.609 | 1.42 (0.65–3.11) | 0.385 | 1.61 (0.71–3.66) | 0.258 |
| Tertile 3 | 16/351 (4.6%) | 1.34 (0.63–2.84) | 0.445 | 1.61 (0.72–3.62) | 0.249 | 1.88 (0.78–4.51) | 0.160 |
| p value for trend across tertiles | NA | 1.15 (0.80–1.67) | 0.448 | 1.26 (0.85–1.88) | 0.253 | 1.35 (0.88–2.07) | 0.167 |
| per log unit increase | NA | 1.17 (0.89–1.52) | 0.256 | 1.25 (0.95–1.66) | 0.116 | 1.34 (0.99–1.81) | 0.060 |
Note:
Model 1 covariates: age, sex, treatment assignment (Atrasentan or Placebo)
Model 2 covariates: age, sex, treatment assignment (Atrasentan or Placebo), race, BMI, eGFR, log(UACR), SBP, DBP
Model 3 covariates: age, sex, treatment assignment (Atrasentan or Placebo), race, BMI, eGFR, log(UACR), SBP, DBP, hemoglobin, insulin use, cardiovascular disease history, log(BNP)